Building a 3D Brain Atlas

Texas Biomed will help map the developing brain with unprecedented detail for the National Institutes of Health’s BRAIN Initiative Cell Atlas Network (BICAN). NIH recently awarded a total of $500 million to 11 teams that will work together to build a 3D brain atlas at single cell resolution over the next five years.

Texas Biomed and its Southwest National Primate Research Center are part of a team led by the University of California, San Francisco (UCSF), and also includes Yale University, University of Pennsylvania, University of Wisconsin - Madison, and University of California, Los Angeles.

"This is an example of what you could call 'Big science' with a capital B," says UCSF Professor Arnold Kriegstein, MD, PhD, who is overseeing the team's $36.4 million portion of the initiative. "It's much larger than any individual lab, or even a single institute, could hope to accomplish. It can only be done with a large collaborative group of investigators working together."

The team's contribution to the overall effort is mapping the developing brain - identifying cell types, activities and locations as they differentiate during development and change throughout childhood and into adolescence. They will also be the only team to draw direct comparisons between humans and nonhuman primate relatives.

"We are truly excited to be a part of this collaboration and see this 3D single cell brain map come to life," says Texas Biomed Associate Professor Marcel Daadi, PhD, one of the co-principal investigators of the NIH grant. "This project will help us better understand what makes our brains different and uniquely vulnerable to certain neurodegenerative diseases compared to our closest relatives."

By mapping female and male developing brains at key phases before birth, after birth, during childhood and teen years, the group aims to learn more about normal, healthy brain development. This will also provide a baseline to better understand how diseases like autism, schizophrenia and Parkinson's emerge.

"Usually, by the time we see symptoms of Parkinson's, about 80% of dopamine nerve terminals are already gone," Dr. Daadi says. "Changes in the brain that happen early in life might contribute to faulty brain connections and neurodegeneration in later years. This project could help us learn what those critical changes are and find new treatment targets."

This builds on the BRAIN Initiative’s first phase, called the Cell Census Network, which catalogued brain cell types, with an emphasis on mice. Now, in this phase, the teams will complete a comprehensive list of human brain cell types, and clarify how all those cells work together, showing what cell types are present in different structures of the brain.

"There are 80 billion cells in the brain and we don't really understand the composition, how those cells are distributed, or how that changes during development," Dr. Kriegstein says. "But we have technology now that allows us to look at these questions at extremely high resolution."

To create the atlas, researchers will not just identify individual cells, but also where they are located in the brain, which can shift, especially during development. They will use a combination of advanced single cell sequencing techniques as well as advanced imaging techniques to ultimately merge the data into an interactive map. A key feature of the BRAIN Initiative is making sure all teams are using standardized methods and technologies so all the data can be compiled together into a final product.

"When complete, the single-cell brain atlas will provide a resource that will inform future research into a wide range of health conditions for decades to come," says Joanne Turner, PhD, Texas Biomed's Executive Vice President of Research. "We are proud to contribute our expertise in animal models and can’t wait to see what new mechanisms are revealed."

The collaboration will also greatly benefit up-and-coming researchers, and is poised to inspire the next generation of scientists and leaders, much like the Human Genome Project did in the 1990s and early 2000s.

"I really think we've put together some of the best experts in the field, anywhere in the world, for this initiative," Dr. Kriegstein says. "I'm really excited for our early-career scientists to work alongside them and with each other on such a significant collaboration."

About Texas Biomed

Texas Biomed is one of the world's leading independent biomedical research institutions dedicated to eradicating infection and advancing health worldwide through innovative biomedical research. Texas Biomed partners with researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, hemorrhagic fever, tuberculosis and parasitic diseases responsible for malaria and schistosomiasis disease. The Institute has programs in host-pathogen interaction, disease intervention and prevention and population health to understand the links between infectious diseases and other diseases such as aging, cardiovascular disease, diabetes and obesity. For more information on Texas Biomed, go to www.TxBiomed.org.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...